The Biostatistics and Bioinformatics Gore serves multiple needs for the planning and conduct of the SPORE'S basic and translational research. The Gore provides hypothesis refinement, experimental design, analysis, data management, and informative presentation of results across all projects of the SPORE. From a biostatistical perspective, design and analysis of laboratory and clinical projects are performed at the direction of Dr. Peter Mueller. Dr.
C aimi ao Wei contributes her expertise to the analysis of microarray and genome data in this SPORE. Data from SPORE clinical trials, animal studies, and laboratory experiments are analyzed with the support of Dr. Chariotte Sun, Mr. Mark Munsell, and Ms. Diana Urbauer. Dr. Jonas Almeida will oversee data base management and data integration. Data integration will build on a new deployment of the existing data service SSDB. This SPORE resource is used to augment existing M.D. Anderson biostatistics and bioinformatics resources and to align these considerable resources with SPORE research objectives.
The Specific Aims ofthe Biostatistics and Bioinformatics Gore are:
Specific Aim 1 : To provide guidance in the design and conduct of clinical trials and other experiments arising from the ongoing research ofthe SPORE.
Specific Aim 2 : To provide the innovative statistical modeling, simulation techniques, and data analyses needed by the Projects, Developmental Projects, and other Gores to achieve their Specific Aims.
Specific Aim 3 : To ensure that the results of all Projects are based on well-designed experiments and are appropriately interpreted.
Specific Aim 4 : Provide a web-based environment where data bases can be created and shared within the multi-institutional Uterine SPORE scientific community.
The Biostatics and Bioinformatics Core will provide statistical and bioinformatics analyses as well as data management to all projects, cores, and developmental research and career development program investigators. The Gore will be involved in all aspects of the projects from the developmental to final evaluation stages and will provide the necessary services to ensure high quality analyses for optimal utilization of data resulting from the SPORE studies.
|Rupaimoole, Rajesha; Calin, George A; Lopez-Berestein, Gabriel et al. (2016) miRNA Deregulation in Cancer Cells and the Tumor Microenvironment. Cancer Discov 6:235-46|
|Srivastava, Akhil; Babu, Anish; Filant, Justyna et al. (2016) Exploitation of Exosomes as Nanocarriers for Gene-, Chemo-, and Immune-Therapy of Cancer. J Biomed Nanotechnol 12:1159-73|
|Yuan, Ying; Hess, Kenneth R; Hilsenbeck, Susan G et al. (2016) Bayesian Optimal Interval Design: A Simple and Well-Performing Design for Phase I Oncology Trials. Clin Cancer Res 22:4291-301|
|Haemmerle, Monika; Bottsford-Miller, Justin; Pradeep, Sunila et al. (2016) FAK regulates platelet extravasation and tumor growth after antiangiogenic therapy withdrawal. J Clin Invest 126:1885-96|
|Westin, Shannon N; Sun, Charlotte C; Tung, Celestine S et al. (2016) Survivors of gynecologic malignancies: impact of treatment on health and well-being. J Cancer Surviv 10:261-70|
|McCampbell, A S; Mittelstadt, M L; Dere, R et al. (2016) Loss of p27 Associated with Risk for Endometrial Carcinoma Arising in the Setting of Obesity. Curr Mol Med 16:252-65|
|Guo, Beibei; Li, Yisheng; Yuan, Ying (2016) A dose-schedule finding design for phase I-II clinical trials. J R Stat Soc Ser C Appl Stat 65:259-272|
|Liu, Joyce; Westin, Shannon N (2016) Rational selection of biomarker driven therapies for gynecologic cancers: The more we know, the more we know we don't know. Gynecol Oncol 141:65-71|
|Wang, Chao; Zhu, Xiaoyong; Feng, Weiwei et al. (2016) Verteporfin inhibits YAP function through up-regulating 14-3-3Ïƒ sequestering YAP in the cytoplasm. Am J Cancer Res 6:27-37|
|Chen, Tenghui; Wang, Zixing; Zhou, Wanding et al. (2016) Hotspot mutations delineating diverse mutational signatures and biological utilities across cancer types. BMC Genomics 17 Suppl 2:394|
Showing the most recent 10 out of 456 publications